FDA to hold digital mammography hearing
The Food and Drug Administration's radiological devices panel of the medical devices advisory committeewill be meeting on March 6 to discuss requirements for submissionsof digital mammography device approval applications. The meetingwill cover the FDA's
The Food and Drug Administration's radiological devices panel of the medical devices advisory committeewill be meeting on March 6 to discuss requirements for submissionsof digital mammography device approval applications. The meetingwill cover the FDA's proposal to regulate full-field-of-view digitalmammography products as class-three devices, a move that wouldrequire vendors to submit premarket approval applications (PMAs)to the FDA (SCAN 1/18/95).
The meeting will begin at 8 a.m. in Conference Room 20G inthe Corporate Building at the FDA's headquarters at 9200 CorporateBlvd., Rockville, MD. Industry comments before the meeting canbe directed to Dr. Steven C. Quay of Sonus Pharmaceuticals, whois serving as the industry representative on the radiologicaldevices panel. Dr. Quay can be reached at Sonus Pharmaceuticals,22026 20th Ave. SE, Suite 102, Bothell, WA 98021. His phone numberis 206/487-9500.
GE HealthCare Launches AI Mammography Platform with Key Applications from iCAD
November 30th 2023Offering an all-in-one platform of artificial intelligence (AI) applications, MyBreastAI Suite reportedly facilitates early breast cancer detection and enhances efficiency with breast imaging workflows.
Study Says Contrast-Enhanced Mammography Offers Comparable Breast Cancer Detection to MRI
November 15th 2023In findings from an enriched cohort of asymptomatic patients with screening-detected abnormalities, researchers found that contrast-enhanced mammography (CEM) was superior to conventional mammography and offered equivalent detection of breast cancer in comparison to breast MRI and abbreviated breast MRI.
What a New Review Reveals About Mammography-Based AI and Breast Cancer Risk Assessment
November 9th 2023Mammography-based artificial intelligence (AI) models demonstrated an 11 percent higher median AUC for predicting breast cancer than traditional clinical risk factors, according to a new systematic review of 16 retrospective studies.
